Management of Hepatorenal Syndrome in Obstructive Liver Disease

Diagnostic Criteria

The American Association for the Study of Liver Diseases recommends that HRS diagnosis requires excluding other causes of acute kidney injury in cirrhotic patients with advanced cirrhosis with ascites, serum creatinine >1.5 mg/dL, no improvement after at least 2 days of diuretic withdrawal and volume expansion with albumin, absence of shock, no current/recent nephrotoxic drug exposure, and absence of parenchymal kidney disease 2
Two types of HRS are recognized: Type 1 HRS (HRS-AKI) and Type 2 HRS, with Type 1 HRS characterized by rapid, progressive renal impairment 2

Bacterial infections, particularly spontaneous bacterial peritonitis (SBP), are the most important risk factors for HRS development, and preventive measures include albumin infusion with antibiotics when treating SBP 2
The European Association for the Study of the Liver recommends norfloxacin (400 mg/day) to reduce HRS incidence in advanced cirrhosis 1
Pentoxifylline (400 mg three times daily) is recommended to prevent HRS in severe alcoholic hepatitis 1

The American College of Gastroenterology recommends terlipressin plus albumin as first-line therapy for type 1 HRS, with an initial dose of 1 mg IV every 4-6 hours 1
Midodrine plus octreotide plus albumin is an alternative pharmacological option, with midodrine titrated up to 12.5 mg orally three times daily and octreotide 200 μg subcutaneously three times daily 3

Careful monitoring of urine output, fluid balance, arterial pressure, and standard vital signs is essential, with central venous pressure ideally monitored to help manage fluid balance 2
Patients with type 1 HRS are generally better managed in intensive or semi-intensive care units 2

Liver transplantation is the definitive treatment for both type 1 and type 2 HRS, with expedited referral for transplantation recommended for patients with type 1 HRS 1
Post-transplant survival rates are approximately 65% in type 1 HRS 1

Untreated HRS has poor prognosis, with median survival of untreated type 1 HRS approximately 1 month 2
High MELD scores and type 1 HRS are associated with very poor prognosis 2

Adequate nutritional support is essential, with daily energy intake of 35-40 kcal/kg and protein intake of 1.2-1.5 g/kg 4
Small frequent meals (4-6 times daily including night snack) improve long-term prognosis 4